JP2024023189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023189A5 JP2024023189A5 JP2023183500A JP2023183500A JP2024023189A5 JP 2024023189 A5 JP2024023189 A5 JP 2024023189A5 JP 2023183500 A JP2023183500 A JP 2023183500A JP 2023183500 A JP2023183500 A JP 2023183500A JP 2024023189 A5 JP2024023189 A5 JP 2024023189A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- cancer
- stage
- ras
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102200006538 rs121913530 Human genes 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 101710113436 GTPase KRas Proteins 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 101150105104 Kras gene Proteins 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024187827A JP2025026853A (ja) | 2018-11-09 | 2024-10-25 | 縮合環化合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018114788 | 2018-11-09 | ||
| CNPCT/CN2018/114788 | 2018-11-09 | ||
| JP2020542808A JP6941241B2 (ja) | 2018-11-09 | 2019-11-08 | 縮合環化合物 |
| JP2021116809A JP7374960B2 (ja) | 2018-11-09 | 2021-07-15 | 縮合環化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021116809A Division JP7374960B2 (ja) | 2018-11-09 | 2021-07-15 | 縮合環化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187827A Division JP2025026853A (ja) | 2018-11-09 | 2024-10-25 | 縮合環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023189A JP2024023189A (ja) | 2024-02-21 |
| JP2024023189A5 true JP2024023189A5 (enExample) | 2024-05-31 |
| JP7579414B2 JP7579414B2 (ja) | 2024-11-07 |
Family
ID=69232886
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542808A Active JP6941241B2 (ja) | 2018-11-09 | 2019-11-08 | 縮合環化合物 |
| JP2021116809A Active JP7374960B2 (ja) | 2018-11-09 | 2021-07-15 | 縮合環化合物 |
| JP2023183500A Active JP7579414B2 (ja) | 2018-11-09 | 2023-10-25 | 縮合環化合物 |
| JP2024187827A Pending JP2025026853A (ja) | 2018-11-09 | 2024-10-25 | 縮合環化合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542808A Active JP6941241B2 (ja) | 2018-11-09 | 2019-11-08 | 縮合環化合物 |
| JP2021116809A Active JP7374960B2 (ja) | 2018-11-09 | 2021-07-15 | 縮合環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187827A Pending JP2025026853A (ja) | 2018-11-09 | 2024-10-25 | 縮合環化合物 |
Country Status (33)
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| WO2020233592A1 (en) | 2019-05-21 | 2020-11-26 | Inventisbio Shanghai Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| PE20221253A1 (es) | 2019-10-28 | 2022-08-16 | Merck Sharp & Dohme | Inhibidores de pequenas moleculas de mutante g12c de kras |
| CN114980976A (zh) * | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| EP4168002A1 (en) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| KR20230049679A (ko) * | 2020-08-12 | 2023-04-13 | 제넨테크, 인크. | 퀴나졸린 화합물의 합성 |
| KR20230053661A (ko) * | 2020-08-17 | 2023-04-21 | 베타 파머수티컬 컴퍼니 리미티드 | 비사이클 화합물과 비사이클 화합물을 포함하는 조성물 및 이들의 용도 |
| CN116368130A (zh) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| JP2023540809A (ja) | 2020-09-11 | 2023-09-26 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤の結晶形態 |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| CN116323624A (zh) * | 2020-09-30 | 2023-06-23 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| WO2022098625A1 (en) * | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CA3201521A1 (en) * | 2020-11-13 | 2022-05-19 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors |
| KR20230088780A (ko) * | 2020-11-13 | 2023-06-20 | 제넨테크, 인크. | 폐암 치료를 위한 krasg12c 억제제 및 pd-l1 결합 길항제를 포함하는 방법 및 조성물 |
| US20240025918A1 (en) * | 2020-11-20 | 2024-01-25 | Jacobio Pharmaceuticals Co., Ltd | KRAS G12D Inhibitors |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| IL303448A (en) * | 2020-12-08 | 2023-08-01 | Genentech Inc | Methods and compositions including a KRASG12C inhibitor and an EGFR inhibitor for the treatment of solid tumors |
| KR20230142465A (ko) | 2020-12-15 | 2023-10-11 | 미라티 테라퓨틱스, 인크. | 아자퀴나졸린 범-KRas 저해제 |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| EP4269405A4 (en) * | 2020-12-22 | 2024-07-24 | Shanghai Kechow Pharma, Inc. | Preparation and application method of heterocyclic compound as kras inhibitor |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| WO2022171013A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 四氢喹唑啉类化合物 |
| CA3207854A1 (en) * | 2021-02-09 | 2022-08-18 | Liansheng Li | Heterocyclic compounds and uses thereof |
| AU2022218927A1 (en) * | 2021-02-09 | 2023-08-03 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| JP2024508755A (ja) * | 2021-02-16 | 2024-02-28 | セラス， インコーポレイテッド | Ｋｒａｓを阻害するための組成物及び方法 |
| US20250255868A1 (en) * | 2021-04-09 | 2025-08-14 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound acting as kras g12d inhibitor |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| US20240239788A1 (en) * | 2021-04-16 | 2024-07-18 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12d mutant |
| WO2022232331A1 (en) * | 2021-04-29 | 2022-11-03 | Amgen Inc. | Heterocyclic compounds and methods of use |
| WO2022246459A1 (en) * | 2021-05-19 | 2022-11-24 | Genentech, Inc. | Combination therapy |
| CN117813306A (zh) * | 2021-05-22 | 2024-04-02 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| WO2022251496A1 (en) * | 2021-05-26 | 2022-12-01 | Cornell University | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer |
| EP4387971A1 (en) * | 2021-08-18 | 2024-06-26 | Jacobio Pharmaceuticals Co., Ltd. | N-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine derivatives and uses thereof |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| TW202327569A (zh) | 2021-09-01 | 2023-07-16 | 瑞士商諾華公司 | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 |
| CN118302162A (zh) * | 2021-11-24 | 2024-07-05 | 默沙东有限责任公司 | Kras突变蛋白的小分子抑制剂 |
| JP2024541508A (ja) | 2021-11-24 | 2024-11-08 | ジェネンテック， インコーポレイテッド | 治療用インダゾール化合物およびがんの治療における使用方法 |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| MX2024007780A (es) | 2021-12-22 | 2024-09-11 | Univ California | Inhibidores de unión covalente de mutantes g12s, g12d y/o g12e de k-ras gtpasa. |
| TW202337466A (zh) * | 2022-01-06 | 2023-10-01 | 美商德洛斯股份有限公司 | 用於抑制ｒａｓ之組合物及方法 |
| US20250084079A1 (en) * | 2022-01-06 | 2025-03-13 | Theras, Inc. | Compositions and methods for inhibition of ras |
| CN118742544A (zh) * | 2022-02-07 | 2024-10-01 | 基因泰克公司 | 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式 |
| IL314604A (en) | 2022-02-07 | 2024-09-01 | Genentech Inc | A process for the synthesis of quinazoline compounds |
| CA3244383A1 (en) | 2022-03-11 | 2023-09-14 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND RELATED USES |
| US20250177406A1 (en) | 2022-03-31 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| KR20240167654A (ko) | 2022-04-06 | 2024-11-27 | 제넨테크, 인크. | 암의 치료를 위한 gdc-6036 및 gdc-0077을 포함하는 병용 요법 |
| JP7735594B2 (ja) | 2022-05-19 | 2025-09-08 | ジェネンテック， インコーポレイテッド | アザ四環式オキサゼピン化合物及びその使用 |
| CN115043729B (zh) * | 2022-07-04 | 2024-09-27 | 青岛大学 | 一种2,2’-二氟联芳基化合物的不对称合成方法 |
| JP2025525946A (ja) | 2022-08-05 | 2025-08-07 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| CN119677726A (zh) | 2022-08-11 | 2025-03-21 | 百时美施贵宝公司 | Kras抑制剂 |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| IL320913A (en) | 2022-11-21 | 2025-07-01 | Treeline Biosciences Inc | Spirocyclic dihydropyranopyrimidine KRAS inhibitors |
| CN117085515A (zh) * | 2023-01-15 | 2023-11-21 | 安徽科博瑞环境科技有限公司 | 低表面能抗污染中空纤维膜的制备装置 |
| CN120548318A (zh) * | 2023-01-18 | 2025-08-26 | 苏州赞荣医药科技有限公司 | Kras g12d抑制剂和其用途 |
| EP4655298A1 (en) * | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| CN116396202A (zh) * | 2023-04-17 | 2023-07-07 | 南京优氟医药科技有限公司 | 一种（2s，4s）-4-氟代吡咯烷-2-羧酸的制备方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250000802A1 (en) | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
| WO2025010415A1 (en) * | 2023-07-05 | 2025-01-09 | The Regents Of The University Of California | Gtpase inhibitors and uses thereof |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002557A1 (en) | 1997-07-11 | 1999-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V | Novel pharmaceutically active compounds interacting with gtp-binding proteins |
| KR20110033223A (ko) | 2008-06-20 | 2011-03-30 | 제넨테크, 인크. | 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법 |
| CN104379563B (zh) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| UA119971C2 (uk) * | 2013-10-10 | 2019-09-10 | Араксіс Фарма Ллк | Інгібітори g12c kras |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | PROCESS FOR SCREENING INHIBITORS OF RAS |
| CA3005089A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| TW201906832A (zh) | 2017-05-25 | 2019-02-16 | 美商亞瑞克西斯製藥公司 | 用於癌症治療之化合物及其使用方法 |
| JP2020521740A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体 |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| SG11202005547YA (en) | 2017-12-19 | 2020-07-29 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
-
2019
- 2019-11-08 BR BR112021008986-1A patent/BR112021008986A2/pt unknown
- 2019-11-08 SG SG11202103298QA patent/SG11202103298QA/en unknown
- 2019-11-08 EP EP19842848.4A patent/EP3735299B1/en active Active
- 2019-11-08 MA MA51530A patent/MA51530B1/fr unknown
- 2019-11-08 KR KR1020237033977A patent/KR102751492B1/ko active Active
- 2019-11-08 MY MYPI2021002582A patent/MY196726A/en unknown
- 2019-11-08 HU HUE19842848A patent/HUE069365T2/hu unknown
- 2019-11-08 SI SI201930862T patent/SI3735299T1/sl unknown
- 2019-11-08 TW TW108140719A patent/TWI784209B/zh active
- 2019-11-08 KR KR1020257000144A patent/KR20250012188A/ko active Pending
- 2019-11-08 HR HRP20241581TT patent/HRP20241581T1/hr unknown
- 2019-11-08 IL IL282916A patent/IL282916B2/en unknown
- 2019-11-08 PE PE2021000682A patent/PE20211504A1/es unknown
- 2019-11-08 DK DK19842848.4T patent/DK3735299T3/da active
- 2019-11-08 CR CR20210229A patent/CR20210229A/es unknown
- 2019-11-08 CA CA3087089A patent/CA3087089C/en active Active
- 2019-11-08 ES ES19842848T patent/ES3004042T3/es active Active
- 2019-11-08 LT LTEPPCT/US2019/060578T patent/LT3735299T/lt unknown
- 2019-11-08 CN CN202410280860.9A patent/CN118084866A/zh active Pending
- 2019-11-08 RS RS20241331A patent/RS66280B1/sr unknown
- 2019-11-08 UA UAA202101478A patent/UA127930C2/uk unknown
- 2019-11-08 PL PL19842848.4T patent/PL3735299T3/pl unknown
- 2019-11-08 KR KR1020207024122A patent/KR102587544B1/ko active Active
- 2019-11-08 AU AU2019377130A patent/AU2019377130B2/en active Active
- 2019-11-08 EP EP24198360.0A patent/EP4483881A3/en active Pending
- 2019-11-08 CN CN202410281087.8A patent/CN118084870A/zh active Pending
- 2019-11-08 WO PCT/US2019/060578 patent/WO2020097537A2/en not_active Ceased
- 2019-11-08 AR ARP190103302A patent/AR117194A1/es unknown
- 2019-11-08 US US16/679,104 patent/US11236068B2/en active Active
- 2019-11-08 SM SM20240487T patent/SMT202400487T1/it unknown
- 2019-11-08 CN CN202410280943.8A patent/CN118084867A/zh active Pending
- 2019-11-08 CN CN202410281112.2A patent/CN118084868A/zh active Pending
- 2019-11-08 PT PT198428484T patent/PT3735299T/pt unknown
- 2019-11-08 MX MX2021005428A patent/MX2021005428A/es unknown
- 2019-11-08 FI FIEP19842848.4T patent/FI3735299T3/fi active
- 2019-11-08 JP JP2020542808A patent/JP6941241B2/ja active Active
- 2019-11-08 CN CN201980026181.6A patent/CN112105419B/zh active Active
- 2019-11-08 TW TW111140273A patent/TWI883352B/zh active
-
2021
- 2021-05-04 CL CL2021001171A patent/CL2021001171A1/es unknown
- 2021-05-07 CO CONC2021/0005987A patent/CO2021005987A2/es unknown
- 2021-05-07 MX MX2025002980A patent/MX2025002980A/es unknown
- 2021-05-07 MX MX2025002979A patent/MX2025002979A/es unknown
- 2021-05-07 MX MX2025002975A patent/MX2025002975A/es unknown
- 2021-05-07 PH PH12021551065A patent/PH12021551065A1/en unknown
- 2021-05-07 MX MX2024008118A patent/MX2024008118A/es unknown
- 2021-07-15 JP JP2021116809A patent/JP7374960B2/ja active Active
- 2021-12-17 US US17/644,993 patent/US12084429B2/en active Active
-
2022
- 2022-03-01 AU AU2022201413A patent/AU2022201413B9/en active Active
- 2022-03-22 CL CL2022000698A patent/CL2022000698A1/es unknown
-
2023
- 2023-10-25 JP JP2023183500A patent/JP7579414B2/ja active Active
-
2024
- 2024-02-13 AU AU2024200904A patent/AU2024200904A1/en active Pending
- 2024-02-29 IL IL311187A patent/IL311187B1/en unknown
- 2024-06-18 US US18/747,054 patent/US20250059163A1/en active Pending
- 2024-10-25 JP JP2024187827A patent/JP2025026853A/ja active Pending
-
2025
- 2025-10-20 IL IL324078A patent/IL324078A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023189A5 (enExample) | ||
| JP2025020147A5 (enExample) | ||
| US20220387384A1 (en) | Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors | |
| EP1778215B1 (en) | Anticancer effect enhancer | |
| JP2011511071A (ja) | 肺癌を治療するためのピコプラチンおよびアムルビシン | |
| JP2018526376A5 (enExample) | ||
| JPWO2021121367A5 (enExample) | ||
| JP2020514311A5 (enExample) | ||
| WO2022258977A1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| JP2009538327A5 (enExample) | ||
| Gong et al. | Intratumor microbiota: a novel tumor component | |
| Lee et al. | A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma. | |
| CN107773556A (zh) | 一种具有抗肿瘤药物功效的联合用药物 | |
| JP2019524888A5 (enExample) | ||
| JPWO2022269525A5 (enExample) | ||
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| EP2754441A2 (en) | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | |
| TW202329946A (zh) | 用於治療癌症之方法及包含cdk2抑制劑之給藥方案 | |
| JPWO2022170060A5 (enExample) | ||
| CN110840892A (zh) | 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途 | |
| Isla et al. | Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study) | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| JPWO2021263026A5 (enExample) | ||
| TW202120085A (zh) | 抗ccr4抗體抵抗性之癌症的治療劑 | |
| JPWO2022246459A5 (enExample) |